Table of Contents Author Guidelines Submit a Manuscript
Malaria Research and Treatment
Volume 2014, Article ID 759392, 9 pages
http://dx.doi.org/10.1155/2014/759392
Research Article

Pharmacokinetic Study and Bioavailability of a Novel Synthetic Trioxane Antimalarial Compound 97/63 in Rats

1Pharmacokinetics and Metabolism Division, CSIR-Central Drug Research Institute, Lucknow 226001, India
2Medicinal and Process Chemistry Division, CSIR-Central Drug Research Institute, Lucknow 226001, India

Received 17 May 2014; Revised 20 July 2014; Accepted 20 July 2014; Published 11 September 2014

Academic Editor: Polrat Wilairatana

Copyright © 2014 Hari Narayan Kushwaha et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Q.-G. Li, J. O. Peggins, L. L. Fleckenstein, K. Masonic, M. H. Heiffer, and T. G. Brewer, “The pharmacokinetics and bioavailability of dihydroartemisinin, arteether, artemether, artesunic acid and artelinic acid in rats,” Journal of Pharmacy and Pharmacology, vol. 50, no. 2, pp. 173–182, 1998. View at Google Scholar · View at Scopus
  2. Y. Wu, “How might qinghaosu (artemisinin) and related compounds kill the intraerythrocytic malaria parasite? A chemist's view,” Accounts of Chemical Research, vol. 35, no. 5, pp. 255–259, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Robert, O. Dechy-Cabaret, J. Cazelles, and B. Meunier, “From mechanistic studies on artemisinin derivatives to new modular antimalarial drugs,” Accounts of Chemical Research, vol. 35, no. 3, pp. 167–174, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. F. Cheng, J. Shen, X. Luo et al., “Molecular docking and 3-D-QSAR studies on the possible antimalarial mechanism of artemisinin analogues,” Bioorganic and Medicinal Chemistry, vol. 10, no. 9, pp. 2883–2891, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Singh, H. Malik, and S. K. Puri, “Orally active amino functionalized antimalarial 1,2,4-trioxanes,” Bioorganic and Medicinal Chemistry Letters, vol. 14, no. 2, pp. 459–462, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Singh and S. K. Puri, Indian Patent IN 191710, 2004.
  7. C. Singh, N. Gupta, and S. K. Puri, “Photooxygenation of 3-aryl-2-cyclohexenols: synthesis of a new series of antimalarial 1,2,4-trioxanes,” Tetrahedron Letters, vol. 46, no. 2, pp. 205–207, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. A. G. Griesbeck, T. T. El-Idreesy, L.-O. Höinck, J. Lex, and R. Brun, “Novel spiroanellated 1,2,4-trioxanes with high in vitro antimalarial activities,” Bioorganic and Medicinal Chemistry Letters, vol. 15, no. 3, pp. 595–597, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Singh, N. C. Srivastav, and S. K. Puri, “Synthesis and antimalarial activity of 6-cycloalkylvinyl substituted 1,2,4-trioxanes,” Bioorganic & Medicinal Chemistry, vol. 12, no. 22, pp. 5745–5752, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. S. K. Singh, R. P. Singh, and R. C. Gupta, “HPLC-UV method for assaying 99/357, a synthetic trioxane antimalarial derivative in rat and rabbit serum,” Journal of Pharmaceutical and Biomedical Analysis, vol. 36, no. 2, pp. 371–376, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Rautio, H. Kumpulainen, T. Heimbach et al., “Prodrugs: design and clinical applications,” Nature Reviews Drug Discovery, vol. 7, no. 3, pp. 255–270, 2008. View at Google Scholar
  12. N. V. Nagaraja, J. K. Paliwal, and R. C. Gupta, “Choosing the calibration model in assay validation,” Journal of Pharmaceutical and Biomedical Analysis, vol. 20, no. 3, pp. 433–438, 1999. View at Publisher · View at Google Scholar · View at Scopus
  13. V. P. Shah, K. K. Midha, J. W. A. Findlay et al., “Bioanalytical method validation—a revisit with a decade of progress,” Pharmaceutical Research, vol. 17, no. 12, pp. 1551–1557, 2000. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Rajanikanth and R. C. Gupta, “LC fluorescence method for multiple synthetic compounds to rapidly create in vivo pharmacokinetic database utilizing N-in-One dosing,” Journal of Pharmaceutical and Biomedical Analysis, vol. 26, no. 4, pp. 519–530, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Lal, N. Mehrotra, and R. C. Gupta, “Analysis and pharmacokinetics of bulaquine and its major metabolite primaquine in rabbits using an LC-UV method—a pilot study,” Journal of Pharmaceutical and Biomedical Analysis, vol. 32, no. 1, pp. 141–150, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. H. B. Waynforth, Experimental and Surgical Technique in the Rat, Academic Press, London, UK, 1980.
  17. M. Issar, S. K. Singh, B. Mishra, and R. C. Gupta, “A sensitive LC assay for the simultaneous determination of centbutindole and its metabolite in rat serum using fluorescence detection,” Journal of Pharmaceutical and Biomedical Analysis, vol. 27, no. 1-2, pp. 347–353, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Jonathon and H. G. Richard, Transdermal Drug Delivery, Marcel Dekker, Basel, Switzerland, 1989.
  19. V. F. Smollen and L. A. Ball, “Controlled Drug Bioavailability, 3. Bioavailability control by drug delivery system design,” 1983.
  20. V. J. Stella and K. W. Nti-Addae, “Prodrug strategies to overcome poor water solubility,” Advanced Drug Delivery Reviews, vol. 59, no. 7, pp. 677–694, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. C. E. Müller, “Prodrug approaches for enhancing the bioavailability of drugs with low solubility,” Chemistry and Biodiversity, vol. 6, no. 11, pp. 2071–2083, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. V. J. Stella, W. N. A. Charman, and V. H. Naringrekar, “Prodrugs. Do they have advantages in clinical practice?” Drugs, vol. 29, no. 5, pp. 455–473, 1985. View at Publisher · View at Google Scholar · View at Scopus
  23. P. Ettmayer, G. L. Amidon, B. Clement, and B. Testa, “Lessons learned from marketed and investigational prodrugs,” Journal of Medicinal Chemistry, vol. 47, no. 10, pp. 2393–2404, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. R. P. Singh, S. Sabarinath, N. Gautam, R. C. Gupta, and S. K. Singh, “Pharmacokinetic study of the novel, synthetic trioxane antimalarial compound 97-78 in rats using an LC-MS/MS method for quantification,” Arzneimittel-Forschung/Drug Research, vol. 61, no. 2, pp. 120–125, 2011. View at Publisher · View at Google Scholar · View at Scopus